Modulation of Nrf2/HO-1 by Thymoquinone During Cisplatin-Induced Nephrotoxicity

dc.contributor.authorUlu, Ramazan
dc.contributor.authorDogukan, Ayhan
dc.contributor.authorTuzcu, Mehmet
dc.contributor.authorGurel, Ali
dc.contributor.authorMuqbil, Irfana
dc.contributor.authorMohammad, Ramzi M.
dc.contributor.authorŞahin, Kazım
dc.date.accessioned2026-08-12T16:36:08Z
dc.date.issued2013
dc.departmentFırat Üniversitesi
dc.description.abstractOBJECTIVE: Side effects of cisplatin, such as nephrotoxicity, limit its use in chemotherapeutic regimens and indicate an agent that suppresses its toxicity. Thymoquinone (TQ), the predominant bioactive constituent present in black seed oil (Nigella sativa), has antiinflammatory, antioxidant and antitumor effects. We propose a protective mechanism of of TQ on cisplatin-nephrotoxicity in rats that is through modulation of Nrf2-mediated antioxidant induction and reduced inflammation. MATERIAL and METHODS: Twenty-eight male Wistar rats (8 weeks-old) were divided into four groups; Control (vehicle; 0.9% saline, 1 ml/kg body wt., p.o.), TQ (10 mg/kg body weight/day in drinking water for 5 days), cisplatin (a single injection of 7mg/kg body wt, i.p.) and TQ for 5 days in drinking water then a single injection of cisplatin. On day 10, all rats were sacrificed by cervical dislocation, kidneys were removed, and serum urea and creatinine were collected. RESULTS: Serum urea and creatinine levels were significantly higher in cisplatin-treated rats compared with control rats. TQ-treatment significantly decreased serum urea and creatinine levels. Cisplatin-treatment caused significant downregulation of the nuclear NF-E2-related factor-2 (Nrf2), heme oxygenase-1(HO-1) and caused an increase in the levels of nuclear factor-kappa B (NF-ae B). Interestingly, TQ supplementation significantly improved the changes associated with cisplatin nephrotoxicity by increasing the levels of Nrf-2 and HO-1 and decreasing the levels of NF-ae B. CONCLUSION: This study demonstrates the TQ targets NRF2/HO-1 and can be used as a potential agent against cisplatin-induced nephrotoxicity.
dc.identifier.doi10.5262/tndt.2013.1002.09
dc.identifier.endpage187
dc.identifier.issn1300-7718
dc.identifier.issue2
dc.identifier.orcid0000-0002-1329-3143
dc.identifier.orcid0000-0001-9542-5244
dc.identifier.scopus2-s2.0-84878492078
dc.identifier.scopusqualityN/A
dc.identifier.startpage182
dc.identifier.urihttps://doi.org/10.5262/tndt.2013.1002.09
dc.identifier.urihttps://hdl.handle.net/11508/45178
dc.identifier.volume22
dc.identifier.wosWOS:000217181300009
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherTurk Nefroloji Diyaliz Transplantasyon Dergisi
dc.relation.ispartofTurkish Nephrology Dialysis and Transplantation Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectCisplatin
dc.subjectKidney
dc.subjectNrf2
dc.subjectHO-1
dc.subjectThymoquinone
dc.titleModulation of Nrf2/HO-1 by Thymoquinone During Cisplatin-Induced Nephrotoxicity
dc.typeArticle

Dosyalar